Related Experiment Video
Updated: May 8, 2026
07:13
A Rat Model of Pressure Overload Induced Moderate Remodeling and Systolic Dysfunction as Opposed to Overt Systolic Heart Failure
Published on: April 30, 2020
Non-coding RNAs in cardiac remodeling and heart failure
Regalla Kumarswamy1, Thomas Thum
1Institute of Molecular and Translational Therapeutic Strategies, Hannover, Germany.
Circulation Research
|August 31, 2013
Summary
MicroRNAs and long noncoding RNAs offer novel diagnostic and therapeutic strategies for heart failure. This review highlights their role in cardiac remodeling and cardiovascular disease management.
Area of Science:
- Cardiovascular Biology
- Molecular Medicine
- Genetics
Background:
- Heart failure is a major cause of death, particularly in aging populations.
- Improved myocardial infarction treatments increase survival but lead to more cardiac remodeling and heart failure.
- Novel therapeutic strategies for cardiac remodeling and heart failure are urgently needed.
Purpose of the Study:
- To review current microRNA-based diagnostic and therapeutic strategies for cardiac remodeling and heart failure.
- To explore the role of long noncoding RNAs in cardiovascular gene regulation.
- To highlight innovative approaches in cardiovascular disease management.
Main Methods:
- Literature review of microRNA and long noncoding RNA research in cardiovascular diseases.
- Analysis of gene regulatory mechanisms in cardiac remodeling.
- Synthesis of current clinical and preclinical findings.
Main Results:
- MicroRNAs are potent regulators of cardiovascular diseases, offering diagnostic and therapeutic potential.
- Long noncoding RNAs represent an additional layer of genomic regulation in the cardiovascular system.
- Current approaches show promise but novel strategies are still scarce.
Conclusions:
- MicroRNAs and long noncoding RNAs are critical players in cardiac remodeling and heart failure.
- Targeting these noncoding RNAs presents a promising avenue for future cardiovascular therapies.
- Further research is essential to translate these findings into effective clinical treatments.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:17Pathophysiology of Heart Failure
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
01:25Cardiomyopathy I: Introduction and Classification
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
02:39lncRNA - Long Non-coding RNAs
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...